Atlas Trials

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

Clinical trial NCT05950945 · RECRUITING

Trial details

NCT number
NCT05950945
Sponsor
Daiichi Sankyo
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Breast Cancer
Start date
2023-12-30
Primary completion
2027-10-01
Enrollment
250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.